Characterization of alternative spliceoforms and the RNA splicing machinery in pancreatic cancer

Patricia E. Carrigan, Jonathan L. Bingham, Subha Srinvasan, Teresa A. Brentnall, Laurence J Miller

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

OBJECTIVES AND METHODS: Alternative splicing provides proteomic diversity that can have profound effects. The extent, pattern, and roles of alternative splicing in pancreatic cancer have not been systematically investigated. We have utilized a spliceoform-specific microarray and polymerase chain reaction to evaluate all known splice variants in human pancreatic cancer cell lines representing a spectrum of differentiation, from near-normal HPDE6 to Capan-1 and poorly differentiated MiaPaCa2 cells. Validation of altered spliceoforms was verified in primary cancer specimens and normal pancreatic ductal cells. In addition, expression of 92 spliceosomal genes was examined to better understand the mechanism for observed differences in mRNA splicing. RESULTS: A statistically significant reduction in alternative splicing was found in the pancreatic cancer cell lines compared with HPDE6 cells. Many splice variants identified in Capan-1 and MiaPaCa2 cells were observed in grades 3 and 4 tumors. Analysis of genes encoding spliceosomal proteins revealed that 28 of 92 genes had significantly decreased expression in cancer compared with normal pancreas. CONCLUSIONS: Pancreatic cancer has reduced alternative splicing diversity compared with normal pancreas. This is demonstrated in both cell lines and primary tumors, with the loss in splicing diversity correlated with relative reduction in expression of spliceosomal genes.

Original languageEnglish (US)
Pages (from-to)281-288
Number of pages8
JournalPancreas
Volume40
Issue number2
DOIs
StatePublished - Mar 2011

Fingerprint

Alternative Splicing
Pancreatic Neoplasms
Pancreas
Genes
Cell Line
Neoplasms
Tumor Cell Line
Proteomics
Gene Expression
Polymerase Chain Reaction
Messenger RNA
Proteins

Keywords

  • alternative splicing
  • microarray
  • pancreatic cancer

ASJC Scopus subject areas

  • Hepatology
  • Internal Medicine
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Characterization of alternative spliceoforms and the RNA splicing machinery in pancreatic cancer. / Carrigan, Patricia E.; Bingham, Jonathan L.; Srinvasan, Subha; Brentnall, Teresa A.; Miller, Laurence J.

In: Pancreas, Vol. 40, No. 2, 03.2011, p. 281-288.

Research output: Contribution to journalArticle

Carrigan, Patricia E. ; Bingham, Jonathan L. ; Srinvasan, Subha ; Brentnall, Teresa A. ; Miller, Laurence J. / Characterization of alternative spliceoforms and the RNA splicing machinery in pancreatic cancer. In: Pancreas. 2011 ; Vol. 40, No. 2. pp. 281-288.
@article{8a348bce8e7942bea0809ff71cd5b9fc,
title = "Characterization of alternative spliceoforms and the RNA splicing machinery in pancreatic cancer",
abstract = "OBJECTIVES AND METHODS: Alternative splicing provides proteomic diversity that can have profound effects. The extent, pattern, and roles of alternative splicing in pancreatic cancer have not been systematically investigated. We have utilized a spliceoform-specific microarray and polymerase chain reaction to evaluate all known splice variants in human pancreatic cancer cell lines representing a spectrum of differentiation, from near-normal HPDE6 to Capan-1 and poorly differentiated MiaPaCa2 cells. Validation of altered spliceoforms was verified in primary cancer specimens and normal pancreatic ductal cells. In addition, expression of 92 spliceosomal genes was examined to better understand the mechanism for observed differences in mRNA splicing. RESULTS: A statistically significant reduction in alternative splicing was found in the pancreatic cancer cell lines compared with HPDE6 cells. Many splice variants identified in Capan-1 and MiaPaCa2 cells were observed in grades 3 and 4 tumors. Analysis of genes encoding spliceosomal proteins revealed that 28 of 92 genes had significantly decreased expression in cancer compared with normal pancreas. CONCLUSIONS: Pancreatic cancer has reduced alternative splicing diversity compared with normal pancreas. This is demonstrated in both cell lines and primary tumors, with the loss in splicing diversity correlated with relative reduction in expression of spliceosomal genes.",
keywords = "alternative splicing, microarray, pancreatic cancer",
author = "Carrigan, {Patricia E.} and Bingham, {Jonathan L.} and Subha Srinvasan and Brentnall, {Teresa A.} and Miller, {Laurence J}",
year = "2011",
month = "3",
doi = "10.1097/MPA.0b013e31820128d2",
language = "English (US)",
volume = "40",
pages = "281--288",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Characterization of alternative spliceoforms and the RNA splicing machinery in pancreatic cancer

AU - Carrigan, Patricia E.

AU - Bingham, Jonathan L.

AU - Srinvasan, Subha

AU - Brentnall, Teresa A.

AU - Miller, Laurence J

PY - 2011/3

Y1 - 2011/3

N2 - OBJECTIVES AND METHODS: Alternative splicing provides proteomic diversity that can have profound effects. The extent, pattern, and roles of alternative splicing in pancreatic cancer have not been systematically investigated. We have utilized a spliceoform-specific microarray and polymerase chain reaction to evaluate all known splice variants in human pancreatic cancer cell lines representing a spectrum of differentiation, from near-normal HPDE6 to Capan-1 and poorly differentiated MiaPaCa2 cells. Validation of altered spliceoforms was verified in primary cancer specimens and normal pancreatic ductal cells. In addition, expression of 92 spliceosomal genes was examined to better understand the mechanism for observed differences in mRNA splicing. RESULTS: A statistically significant reduction in alternative splicing was found in the pancreatic cancer cell lines compared with HPDE6 cells. Many splice variants identified in Capan-1 and MiaPaCa2 cells were observed in grades 3 and 4 tumors. Analysis of genes encoding spliceosomal proteins revealed that 28 of 92 genes had significantly decreased expression in cancer compared with normal pancreas. CONCLUSIONS: Pancreatic cancer has reduced alternative splicing diversity compared with normal pancreas. This is demonstrated in both cell lines and primary tumors, with the loss in splicing diversity correlated with relative reduction in expression of spliceosomal genes.

AB - OBJECTIVES AND METHODS: Alternative splicing provides proteomic diversity that can have profound effects. The extent, pattern, and roles of alternative splicing in pancreatic cancer have not been systematically investigated. We have utilized a spliceoform-specific microarray and polymerase chain reaction to evaluate all known splice variants in human pancreatic cancer cell lines representing a spectrum of differentiation, from near-normal HPDE6 to Capan-1 and poorly differentiated MiaPaCa2 cells. Validation of altered spliceoforms was verified in primary cancer specimens and normal pancreatic ductal cells. In addition, expression of 92 spliceosomal genes was examined to better understand the mechanism for observed differences in mRNA splicing. RESULTS: A statistically significant reduction in alternative splicing was found in the pancreatic cancer cell lines compared with HPDE6 cells. Many splice variants identified in Capan-1 and MiaPaCa2 cells were observed in grades 3 and 4 tumors. Analysis of genes encoding spliceosomal proteins revealed that 28 of 92 genes had significantly decreased expression in cancer compared with normal pancreas. CONCLUSIONS: Pancreatic cancer has reduced alternative splicing diversity compared with normal pancreas. This is demonstrated in both cell lines and primary tumors, with the loss in splicing diversity correlated with relative reduction in expression of spliceosomal genes.

KW - alternative splicing

KW - microarray

KW - pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=79951726838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951726838&partnerID=8YFLogxK

U2 - 10.1097/MPA.0b013e31820128d2

DO - 10.1097/MPA.0b013e31820128d2

M3 - Article

C2 - 21178653

AN - SCOPUS:79951726838

VL - 40

SP - 281

EP - 288

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 2

ER -